Filing Flows › IGC Pharma (IGC) › Q3 2026 › vs Q3 2025
IGC Pharma (IGC) Q3 2026 vs Q3 2025 (year over year)
IGC Pharma's revenue rose $137K (+72%) from $191K in Q3 2025 to $328K in Q3 2026. The biggest changes: White Labeling Services +$168K (+110%); Wellness and Lifestyle −$31K (-82%).
IGC Pharma, Q3 2026: revenue $328K (+72% year over year), operating margin -588.7%, net loss $2.0M, operating cash flow −$1.4M. The chart draws each line against Q3 2025, the increases inside each band.
Every line
| Line | Q3 2026 | Q3 2025 | Change | % |
|---|---|---|---|---|
| White Labeling Services | $321K | $153K | $168K | +110% |
| Wellness and Lifestyle | $7K | $38K | −$31K | -82% |
| Revenue | $328K | $191K | $137K | +72% |
| Net loss | $2.0M | $1.8M | $225K | +12% |
| Costs & expenses | $2.4M | $3.1M | −$716K | -23% |
| Operating costs | $2.3M | $3.1M | −$831K | -27% |
| Interest & other, net | $115K | −$1.1M | $1.2M | — |
| Cost of revenue | $267K | $92K | $175K | +190% |
| Research & development | $1.0M | $1.6M | −$575K | -36% |
| SG&A | $979K | $1.4M | −$431K | -31% |
| Operating cash sources | $2.0M | $1.8M | $225K | +12% |
| Depreciation & amortization | $58K | $119K | −$61K | -51% |
| Working capital & other | $571K | −$388K | $959K | — |
| Cash used in operations | $1.4M | $2.1M | −$673K | -32% |
| Net loss absorbed | $2.0M | $1.8M | $225K | +12% |
Questions
How much did IGC Pharma's revenue grow year over year in Q3 2026?
IGC Pharma's revenue rose $137K (+72%) from $191K in Q3 2025 to $328K in Q3 2026.
What drove IGC Pharma's revenue change in Q3 2026?
White Labeling Services +$168K (+110%); Wellness and Lifestyle −$31K (-82%).